Term: drug design
https://doi.org/10.1351/goldbook.DT06960

Definition:
drug design includes not only ligand design, but also pharmacokinetic and toxicity, which are mostly beyond the possibilities of structure- and/or computer-aided design. Nevertheless, appropriate chemometric tools, including experimental design and multivariate statistics, can be of value in the planning and evaluation of pharmacokinetic and toxicological experiments and results. drug design is most often used instead of the correct term 'Ligand Design'.

Related Terms:
1) drug (http://doi.org/10.1351/goldbook.D01863).
2) pharmacokinetic (http://doi.org/10.1351/goldbook.PT06835).
3) toxicity (http://doi.org/10.1351/goldbook.T06414).
4) multivariate statistics (http://doi.org/10.1351/goldbook.MT06974).

Source: PAC, 1997, 69, 1137. 'Glossary of terms used in computational drug design (IUPAC Recommendations 1997)' on page 1142 (https://doi.org/10.1351/pac199769051137)

Citation: 'drug design' in IUPAC Compendium of Chemical Terminology, 5th ed. International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. https://doi.org/10.1351/goldbook.DT06960

License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/) for individual terms.

Disclaimer: The International Union of Pure and Applied Chemistry (IUPAC) is continuously reviewing and, where needed, updating terms in the Compendium of Chemical Terminology (the IUPAC Gold Book). Users of these terms are encouraged to include the version of a term with its use and to check regularly for updates to term definitions that you are using.